TPIDB > Principal Investigator
Principal Investigator
National Taiwan University Hospital
(在職)
Division of Nephrology
Division of General Internal Medicine
更新時間：2025-03-10
周鈺翔CHOU, YU-HSIANG
- Principal Investigator
- Clinical Trial Experience (year) 7 years 9 個月
Publication
12Publications
1
Cheng YT, Tu YC, Chou YH, Lai CF. Protocol for renal ischemia-reperfusion injury by flank incisions in mice. STAR Protoc. 2022 Dec 16;3(4):101678. doi: 10.1016/j.xpro.2022.101678. Epub 2022 Oct 7. PMID: 36208451; PMCID: PMC9562430.
2
Chiu YL, Lin WC, Shu KH, Fang YW, Chang FC, Chou YH, Wu CF, Chiang WC, Lin SL, Chen YM, Wu MS. Alternative Complement Pathway Is Activated and Associated with Galactose-Deficient IgA1 Antibody in IgA Nephropathy Patients. Front Immunol. 2021 Jun 10;12:638309. doi: 10.3389/fimmu.2021.638309. PMID: 34177889; PMCID: PMC8223746.
3
Chou YH, Chen YM. Aging and Renal Disease: Old Questions for New Challenges. Aging Dis. 2021 Apr 1;12(2):515-528. doi: 10.14336/AD.2020.0703. PMID: 33815880; PMCID: PMC7990354.
4
Chou YH, Lai TS, Lin YC, Chiang WC, Chu TS, Lin SL, Chen YM. Age-Dependent Effects of Acute Kidney Injury on End-Stage Kidney Disease and Mortality in Patients with Moderate to Severe Chronic Kidney Disease. Nephron. 2023 Jan 17:1-8. doi: 10.1159/000528021. Epub ahead of print. PMID: 36649699.
5
Chou YH, Lu FP, Chen JH, Wen CJ, Lin KP, Chou YC, Wu MC, Chen YM. Restoration of dysnatremia and acute kidney injury benefits outcomes of acute geriatric inpatients. Sci Rep. 2021 Oct 11;11(1):20097. doi: 10.1038/s41598-021-99677-z. PMID: 34635719; PMCID: PMC8505420.
6
Chou YH, Pan SY, Lin SL. Pleotropic effects of hypoxia-inducible factor-prolyl hydroxylase domain inhibitors: are they clinically relevant? Kidney Res Clin Pract. 2023 Jan;42(1):27-38. doi: 10.23876/j.krcp.22.118. Epub 2022 Nov 21. PMID: 36634968; PMCID: PMC9902737.
7
Chou YH, Pan SY, Shao YH, Shih HM, Wei SY, Lai CF, Chiang WC, Schrimpf C, Yang KC, Lai LC, Chen YM, Chu TS, Lin SL. Methylation in pericytes after acute injury promotes chronic kidney disease. J Clin Invest. 2020 Sep 1;130(9):4845-4857. doi: 10.1172/JCI135773. PMID: 32749240; PMCID: PMC7456210.
8
Lin SY, Feng JY, Lee CY, Lin YC, Chou YH, Lin KY, Wei YF, Lin SW, Chang CH, Wang PH, Shu CC, Wang JY, Yu CJ. Completion and Adverse Drug Events of Latent Tuberculosis Infection Treatment in Patients Receiving Dialysis: Predictors and Impacts of Different Regimens in a Prospective Cohort Study. Antimicrob Agents Chemother. 2021 Feb 17;65(3):e02184-20. doi: 10.1128/AAC.02184-20. PMID: 33361292; PMCID: PMC8092540.
9
Lin YC, Lai TS, Wu HY, Chou YH, Chiang WC, Lin SL, Chen YM, Chu TS, Tu YK. Effects and Safety of Statin and Ezetimibe Combination Therapy in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Clin Pharmacol Ther. 2020 Oct;108(4):833-843. doi: 10.1002/cpt.1859. Epub 2020 May 13. PMID: 32320058.
10
Pan SY, Tsai PZ, Chou YH, Chang YT, Chang FC, Chiu YL, Chiang WC, Hsu T, Chen YM, Chu TS, Lin SL. Kidney pericyte hypoxia-inducible factor regulates erythropoiesis but not kidney fibrosis. Kidney Int. 2021 Jun;99(6):1354-1368. doi: 10.1016/j.kint.2021.01.017. Epub 2021 Mar 31. PMID: 33812664.
1
2
